

Special Issue

Nanosystems and Antibody/Peptide Modified Drugs for Cancer Treatment

Message from the Guest Editors

Currently, the first line of treatment in cancers is the surgical removal of solid tumors. After primary surgical resection, the main action includes the intravenous administration of systemic chemotherapy treatments using cytotoxic molecules. In addition, a specific applied chemotherapeutic treatment may be ineffective due to multidrug resistance (MDR), caused by the resistance of some remaining cancer cells due to the lack of a specific targeting. Finally, their systemic and (therefore not localized) administration represents a great disadvantage since these molecules cannot be administered in low doses and/or gradually.

Consequently, it is necessary to discover and develop new chemical formulations capable of improving their antitumor efficiencies in terms of activity and selectivity, compared with conventional chemotherapeutic drugs, currently approved for cancer therapy. The Topic presented here aims to solve specific problems associated with cancer recurrence through the development of new antibody/peptide derivatives and analogues with higher antitumor activity, low unwanted secondary effects and better viability compared with the current chemotherapeutic drugs.

Guest Editors

Prof. Dr. Juan Manuel López Romero

Department of Organic Chemistry, Faculty of Sciences, University of Málaga, 29071 Málaga, Spain

Prof. Dr. Francisco Sarabia

Department of Organic Chemistry, Faculty of Science, University of Málaga, 29071 Málaga, Spain

Deadline for manuscript submissions

30 April 2025



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed



mdpi.com/si/168007

Pharmaceutics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).